Cathie Wood's ARK buys Veracyte, sells AvidXchange and 3D Systems stock

On June 6th, 2025, ARK ETFs increased their position in Veracyte Inc (VCYT) by purchasing 30,771 shares for $830,201, signaling continued confidence in the genomic diagnostics company. Conversely, ARK reduced its holdings in AvidXchange Holdings Inc (AVDX) by selling 10,025 shares for $98,044 and trimmed its 3D Systems Corp (DDD) stake by 1,600 shares for $2,672. These trades reflect a broader trend over the past week of ARK reducing exposure to companies like AVDX, Coinbase (COIN), and Palantir (PLTR) while increasing investments in Veracyte and Guardant Health (GH).

Analysis

ARK ETFs' daily trading disclosure for June 6th, 2025, reveals a continued strategic emphasis on the healthcare sector, particularly genomics. The flagship ARKK fund acquired an additional 30,771 shares of Veracyte Inc (VCYT) for $830,201, reinforcing a pattern of recent accumulation and signaling heightened conviction in the genomic diagnostics company. This contrasts with divestments in other areas: ARKF reduced its AvidXchange Holdings Inc (AVDX) position by selling 10,025 shares valued at $98,044, a minor trim in its fintech exposure. Furthermore, a small sale of 1,600 shares of 3D Systems Corp (DDD) for $2,672, distributed across ARKQ and ARKX ETFs, suggests a diminishing interest in 3D printing. These individual transactions align with a broader weekly trend where ARK has consistently sold shares in AVDX, Coinbase Global Inc (COIN), and Palantir Technologies Inc (PLTR), while actively increasing holdings in VCYT and Guardant Health Inc (GH). These portfolio adjustments indicate dynamic repositioning by ARK, likely reflecting evolving market assessments and a reinforced long-term belief in specific healthcare and genomic companies over certain fintech and technology names.

Key Decisions for Investors

• Investors should note ARK's pronounced bullish stance on Veracyte (VCYT) and Guardant Health (GH), evidenced by multiple purchases, potentially warranting a closer look at the growth prospects within the genomic diagnostics and healthcare sectors.
• The consistent selling of AvidXchange (AVDX), Coinbase (COIN), Palantir (PLTR), and the trimming of 3D Systems (DDD) may signal ARK's reduced conviction; investors holding these names might consider reviewing their positions in light of this selling pressure.
• Observe ARK's strategic reallocation as a potential indicator of broader thematic shifts, particularly the increased weighting towards specialized healthcare and a possible cooling on specific segments of fintech and disruptive technology.